(Q40354761)

19 September 2017

title

Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice (English)

1 reference

19 September 2017

1 reference

5

Dominique Heymann

1 reference

19 September 2017

Benjamin Ory

1

1 reference

19 September 2017

Marie-Françoise Heymann

2

1 reference

19 September 2017

Akira Kamijo

3

1 reference

19 September 2017

François Gouin

4

1 reference

19 September 2017

Françoise Redini

6

1 reference

19 September 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

19 September 2017

1 reference

19 September 2017

volume

104

1 reference

19 September 2017

issue

11

1 reference

19 September 2017

page(s)

2522-2529

1 reference

Development of bisphosphonates

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21530

7 January 2021

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21530

7 January 2021

Bisphosphonates: new therapeutic agents for the treatment of bone tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21530

7 January 2021

The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21530

7 January 2021

Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21530

7 January 2021

Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21530

7 January 2021

Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21530

7 January 2021

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21530

7 January 2021

Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21530

7 January 2021

Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21530

7 January 2021

How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21530

7 January 2021

Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21530

7 January 2021

Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21530

7 January 2021

Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21530

7 January 2021

Identifiers

DOI

10.1002/CNCR.21530

1 reference

19 September 2017

1 reference